Study of Botulinum Toxin in Patients With Primary Hyperhidrosis - Full Text View

Study of Botulinum Toxin in Patients With Primary Hyperhidrosis

This study has been completed.

Sponsored by:	Mount Sinai School of Medicine
Information provided by:	Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:	NCT00004480

Purpose

OBJECTIVES:

I. Determine the optimal dose of botulinum toxin necessary to decrease sweating in patients with primary hyperhidrosis.

Condition	Intervention
Hyperhidrosis	Drug: botulinum toxin type A

MedlinePlus related topics:

Botox

Drug Information available for:

Clostridium botulinum toxin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Further study details as provided by Office of Rare Diseases (ORD):

Study Start Date:

July 1999

Detailed Description:

PROTOCOL OUTLINE:

Patients receive injections of botulinum toxin in the clinical trial for 6 months. Patients undergo an iodine starch test and a sympathetic skin response test to assess the efficacy of the drug. Patients also complete questionnaires to evaluate the amount of sweating.

Eligibility

Ages Eligible for Study:	16 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Diagnosis of hyperhidrosis
Excessive sweating in the hands, feet, armpits, forehead, or body

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004480

Locations


United States, New York
	Mount Sinai School of Medicine
	New York, New York, United States, 10029

Sponsors and Collaborators

Mount Sinai School of Medicine

Investigators


Study Chair:	Horacio Kaufmann	Mount Sinai School of Medicine

More Information

Study ID Numbers:	199/14182, MTS-GCO-98-913NE, ALLERGAN-MTS-GCO-98-913NE
First Received:	October 18, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00004480
Health Authority:	Unspecified

Keywords provided by Office of Rare Diseases (ORD):

dermatologic disorders

hyperhidrosis

rare disease

Study placed in the following topic categories:

Botulinum Toxins

Skin Diseases

Rare Diseases

Hyperhidrosis

Botulinum Toxin Type A

Additional relevant MeSH terms:

Anti-Dyskinesia Agents

Therapeutic Uses

Physiological Effects of Drugs

Neuromuscular Agents

Peripheral Nervous System Agents

Sweat Gland Diseases

Central Nervous System Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 30, 2008